Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02266628 · ClinicalTrials.gov registry record · Phase 2
Placebo- Controlled Study to Evaluate the Safety and Immunogenicity of the RSV-F Vaccine in Elderly Adults
A Phase 2 study, sponsored by Novavax.
- Completed
- Registry status
- Phase 2
- Development phase
- 1,599
- Enrollment target
NCT02266628: Completed Phase 2 study, sponsored by Novavax.
NCT02266628 is a Phase 2 study that has completed, run by Novavax. The registered enrollment target is 1,599 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (1102% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02266628, a Phase 2 study, has completed, sponsored by Novavax.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 1,599 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and immunogenicity of the RSV- F Vaccine in elderly subjects, as well as rate the incidence of medically- attended RSV disease in vaccine and placebo recipients.
Primary Outcome
Serum IgG antibody concentrations as ELISA units (EUs) specific for the F protein antigen. Derived/ calculated endpoints based on these data will include: * Geometric mean concentrations as EU (GMEU) * Geometric mean ratio (GMR) * Geometric mean fold-rise( GMFR) * Seroresponse rate (SRR)
Interventions
- BIOLOGICAL RSV-F Vaccine
- BIOLOGICAL Saline Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,599 participants |
| Start Date | 2014-10 |
| Est. Completion | 2016-03 |
| Phase | Phase 2 |
What the finished NCT02266628 record still lists
NCT02266628 is an interventional study that assigns participants to a tested intervention. Its 1,599 participants enrollment target places it among the larger protocols in the corpus, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (1102% higher).
The record links to 0 conditions, and to 2 interventions - of which RSV-F Vaccine is the first listed.
NCT02266628 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02266628 about?
NCT02266628 is a clinical study titled "Placebo- Controlled Study to Evaluate the Safety and Immunogenicity of the RSV-F Vaccine in Elderly Adults". The purpose of this study is to evaluate the safety and immunogenicity of the RSV- F Vaccine in elderly subjects, as well as rate the incidence of medically- attended RSV disease in vaccine and placebo recipients.
What is the current status of trial NCT02266628?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 1,599 participants. The study started on 2014-10. Estimated completion is 2016-03.
What interventions are being tested in trial NCT02266628?
The interventions under investigation include: RSV-F Vaccine (BIOLOGICAL), Saline Placebo (BIOLOGICAL).
Who is sponsoring clinical trial NCT02266628?
This trial is sponsored by Novavax, which has 31 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02266628's enrollment target sits among peer trials
1,599 11th of 2000 higher than 1,990 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00646022 · 1,600 participants
Natural History of Familial Carcinoid Tumor
- NCT03109197 · 1,600 participants
Sudden Unexplained Death in Childhood (SUDC) Registry
- NCT03511118 · 1,600 participants
Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants
- NCT04314401 · 1,600 participants
National Cancer Institute "Cancer Moonshot Biobank"
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia